about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

NIH un­veils a vac­cine can­di­date for uni­ver­sal flu jab as first-in-hu­man stud­ies get un­der­way

7 years ago
R&D

Vas Narasimhan has high hopes for No­var­tis' Chi­na dri­ve as a block­buster drug gets a nod

7 years ago
China

As Spark share­hold­ers balk, FTC holdup helps de­lay Roche's $4.3B buy­out

7 years ago
Deals

Does an im­proved safe­ty pro­file strength­en Al­ler­gan's case for a wet AMD chal­lenge to Lu­cen­tis?

7 years ago
R&D

At­las wraps Arteaus sto­ry with $260M roy­al­ty sale as Em­gal­i­ty sales inch­es up­ward

7 years ago
Pharma

Take­da takes a cau­tious step in­to neu­ro­log­i­cal gene ther­a­py, ink­ing pre­clin­i­cal deal with Stride­Bio

7 years ago
Pharma
Cell/Gene Tx

Sunao Man­abe takes top job at Dai­ichi Sankyo in wake of As­traZeneca deal; CAR-T play­er Celyad pro­motes Fil­ip­po Pet­ti ...

7 years ago
Peer Review

Pre­ci­sion Bio wants to show there's a bet­ter way to ed­it genes — and now it has $126M in IPO cash to prove it

7 years ago
Financing

Promis­ing to match more NSCLC pa­tient with tar­get­ed drugs, Cam­bridge spin­out Ini­va­ta read­ies US launch of liq­uid ...

7 years ago
Financing

As AI per­me­ates clin­i­cal an­a­lyt­ics, Per­cep­tive Ad­vi­sors bets $40M in­to a sto­ried play­er in the field

7 years ago
Financing
AI

Pain free? Meet Cas­sa­va, the newest Alzheimer’s play­er on Nas­daq

7 years ago
R&D

Eight months af­ter fil­ing for IPO, the mak­er of Chi­na's Ebo­la vac­cine joins HKEX with $161M raise

7 years ago
R&D
China

Lit­tle Aldeyra's shares rock­et high­er as its first PhI­II eye drug tri­al scores, clear­ing path to NDA

7 years ago
R&D

Con­tend­ing for CD47 throne, Arch On­col­o­gy scores $50M as it ramps up PhI stud­ies

7 years ago
Financing

Avanir cites 'en­cour­ag­ing' progress in PhI­II pro­gram for Alzheimer's ag­i­ta­tion

7 years ago
R&D

En­tra­da picks Syn­tim­mune vet Mario Saltarel­lo as CMO; Gene ther­a­py mak­er Or­chard hires Ran Zheng as CTO

7 years ago
Peer Review

Hack­ing in­to macrophage at­tack cir­cuits, Stan­ford sci­en­tists pitch a bet­ter ear­ly-warn­ing alert sys­tem for tu­mors

7 years ago
Discovery

Shang­hai-based can­cer drug­mak­er Ab­bisko lines up $42M B round as it makes a leap for the clin­ic

7 years ago
Financing
China

Feng Zhang, heavy­weight col­lab­o­ra­tors un­veil lat­est CRISPR up­start — a di­ag­nos­tic com­pa­ny

7 years ago
Startups

As gener­ic en­try looms for its cash cow, Jazz wins FDA nod for fol­low-up sleep dis­or­der drug

7 years ago
Pharma

NASH drug in hand, Mer­ck forges ahead with 2-year ex­ten­sion of NGM Bio col­lab­o­ra­tion deal

7 years ago
R&D
Pharma

Fol­low­ing Syn­tim­mune buy­out, Alex­ion antes up $25M to dou­ble down on an­ti-FcRn path­way

7 years ago
Pharma

Seek­ing a place among gi­ants in the on­colyt­ic virus field, lit­tle Cold Genesys bags $22M Se­ries C

7 years ago
Financing

Af­fimed lands mile­stone from Roche; Puma touts new PHII da­ta on cer­vi­cal can­cer

7 years ago
News Briefing
First page Previous page 101102103104105106107 Next page Last page
A service from the Financial Times